Previous Close | 246.00 |
Open | 245.00 |
Bid | 250.03 x 13700 |
Ask | 250.16 x 21700 |
Day's Range | 242.00 - 251.16 |
52 Week Range | 242.00 - 332.68 |
Volume | 826,047 |
Avg. Volume | 851,763 |
Market Cap | 113.826B |
Beta (5Y Monthly) | 0.10 |
PE Ratio (TTM) | 42.79 |
EPS (TTM) | 5.85 |
Earnings Date | Feb 18, 2021 |
Forward Dividend & Yield | 2.81 (1.14%) |
Ex-Dividend Date | Mar 04, 2021 |
1y Target Est | 151.95 |
Seqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine (QIVc), for an expanded age indication for people two years of age and older.1 FLUCELVAX QUADRIVALENT was previously FDA-approved for use in persons four years of age and older. FLUCELVAX QUADRIVALENT will be available as a 0.5ml intramuscular (IM) vaccine per dose for the 2021/22 U.S. influenza season.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CSL Limited ( ASX:CSL...
With its stock down 6.4% over the past three months, it is easy to disregard CSL (ASX:CSL). However, a closer look at...